CHEK2 and breast cancer: Furthermore, CHEK2 c.1100delC breast cancer patients were diagnosed with smaller tumors (67.3 % vs 55.0 % of tumors ≤2 cm) but more often lymph node positive disease (44.3 % vs 30.9) compared to non-carriers.